Cabergoline therapy for macroprolactinoma during pregnancy: a case report

Area of Science:

• Reproductive Endocrinology
• Neuroendocrinology
• Oncology

Background:

• Hyperprolactinemia, often caused by pituitary adenomas, requires management.
• Bromocriptine is a common treatment but can cause intolerance.
• Alternative therapies are needed for pregnant patients with hyperprolactinemia.

Observation:

• A 31-year-old woman with uncontrolled hyperprolactinemia and a pituitary macroadenoma was intolerant to Bromocriptine.
• Cabergoline therapy was initiated, leading to symptom improvement and conception.
• Serial MRIs revealed tumor size reduction during pregnancy.

Findings:

• Cabergoline effectively managed hyperprolactinemia in a pregnant patient.
• The patient delivered a healthy infant at 37 weeks gestation.
• Continued Cabergoline therapy during pregnancy was associated with tumor size reduction.

Implications:

• This case supports the safety and efficacy of Cabergoline for treating hyperprolactinemia during pregnancy.
• Further research is warranted to expand the data on Cabergoline use in pregnant patients.
• Cabergoline offers a viable therapeutic option for women with hyperprolactinemia who cannot tolerate Bromocriptine.